Yuankai Shi - Concepedia

Author

Yuankai Shi

Chinese Academy of Medical Sciences & Peking Union Medical College

Also Known As

Jianping Xu, S. Yuankai, Shi Yuankai, Y K Shi, YUANKAI SHI, Yuan-Kai Shi, Yuan-kai Shi, Yuankai Shi

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

Chinese Academy of Medical Sciences & Peking Union Medical College Fudan University Shanghai Cancer Center Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"Sapienza University of Rome Kindai University Hospital

About

Yuankai Shi is an author at Chinese Academy of Medical Sciences & Peking Union Medical College specializing in medicine, cancer research, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	1.2K
2	Health Sciences	2	2	183
3	Public Health	1	1	425
4	Diabetes	1	1	425
5	Global Health	1	1	425

Yuankai Shi

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
The global implications of diabetes and cancer Yuankai Shi, Frank B. Hu The Lancet ObesityMetabolic SyndromeDiabetes ManagementGlobal HealthDiabetes	2014	425
Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma Umberto Vitolo, Marek Trněný, David Belada, Journal of Clinical Oncology Advanced-stage DlbclLymphoid NeoplasiaHematological MalignancyMedicineMalignant Blood Disorder	2017	414
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study Tadeusz Robak, Jie Jin, Halyna Pylypenko, The Lancet Oncology Hematological MalignancyFrontline BortezomibLymphoid NeoplasiaTransplantationOncology	2018	132
Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas Mei Dong, Zhiqiang Ning, Pu-yuan Xing, Cancer Chemotherapy and Pharmacology Lymphoid NeoplasiaOncologyMedicinePathologyAdvanced Solid Tumors	2012	120
miR-130a regulates macrophage polarization and is associated with non-small cell lung cancer Lin Lin, Haibo Lin, Lin Wang, Oncology Reports	2015	56
End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA Lale Kostakoglu, Maurizio Martelli, Laurie H. Sehn, Blood Advances Oncologic ImagingPet-mriPathologyFirst-line TreatmentPositron Emission Tomography	2021	51
Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study Lale Kostakoglu, Federico Mattiello, Maurizio Martelli, Haematologica	2021	47
Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Final Results from an Open-Label, Randomized Phase 3 Study (GOYA) Umberto Vitolo, Marek Trněný, David Belada, Blood	2016	35
Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors Yongkun Sun, Lin Yang, Xuezhi Hao, Journal of Hematology & Oncology	2019	33
Baseline PET-Derived Metabolic Tumor Volume Metrics Predict Progression-Free and Overall Survival in DLBCL after First-Line Treatment: Results from the Phase 3 GOYA Study Lale Kostakoglu, Maurizio Martelli, Laurie H. Sehn, Blood	2017	29

Page 1